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ABSTRACT
Circulating miRNAs are protected from ribonuclease degradation by assembly into 
microvesicles and exosomes. Releasing miRNAs completely from these particles is the 
key step to quantify the circulating miRNAs. Currently purified RNA-based quantitative 
analysis is widely used while it is time and cost consuming with high risk for those 
circulating miRNAs with low abundance due to partial loss of RNA during the steps 
of total RNA extraction and small RNA enrichment. Herein, we optimized a simple, 
effective and time-saving method to directly measure plasma miRNAs without RNA 
isolation. It is based on complete miRNA release from the protein complexes, followed 
by miRNA-specific reverse transcription and quantitative real-time PCR amplification. 
By comparison to the RNA-based approach, the direct quantification method showed 
more efficiency for circulating miRNA analysis, higher accuracy and specificity. By 
application of the direct quantification method to clinical samples combined with 
the RNA-based miRNA screening analysis, upregulation of miR-106a in blood was 
validated in metastatic breast cancer patients, indicating miR-106a are a potential 
biomarker for metastatic breast cancer.
INTRODUCTION
The Human Genome Project has demonstrated that 
more than 93% of the genome DNA can be transcribed to 
RNA while less than 2% of transcripts encode functional 
proteins [1], indicating most of the transcripts are 
non-coding RNAs (ncRNA). Those ncRNAs with length 
< 200 nt are called small non-coding RNAs and include 
transfer RNA (tRNA), ribosomal RNA (rRNA), small 
nuclear RNA (snoRNA), microRNA (miRNA), small 
interference RNA (siRNA) and piwi-interacting RNA 
(piRNA).
miRNAs are a class of multifunctional singled-
stranded small molecules that regulate the stability or 
translational efficiency of targeted messenger RNAs. 
Mature miRNAs have length ranging from 18 to 24 nt. 
More than 2,000 miRNA sequences have been identified 
or predicted from human-origin cells.  miRNAs can be 
assembled into ribonucleic protein complexes known as 
RNA-induced silencing complex (RISC) that lead to base-
pairing interactions between a miRNA and the binding 
site of its target mRNAs mostly within the 3′ untranslated 
region (3′UTR). miRNAs regulate diverse biological 
processes including cell fate determination, cell cycle 
progression, stem cell self-renewal,  cancer initiation, 
cancer cell proliferation and cancer cell metastasis [2–8].
miRNAs are present in body fluids including 
blood, plasma, serum, saliva, urine and milk [9–12]. The 
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extracellular miRNAs circulating in the blood of both 
healthy and diseased people, are referred to circulating 
miRNAs. Most of the circulating miRNAs are protected 
from ribonuclease degradation by cofractionating with 
proteins or assembling in lipid or lipoprotein complexes, 
such as microvesicles and/or exosomes [13, 14]. Therefore, 
circulating miRNAs are highly stable in blood. Although 
the understanding of how miRNAs are selectively released 
from cells and how the circulating miRNAs are related to 
disease remains largely unclear, circulating miRNAs may 
serve as novel diagnostic and prognostic biomarkers for 
human diseases including cancer [15]. Emerging evidence 
suggests secreted miRNAs function as heterotypic 
signals to regulate the breast cancer phenotype [16] and 
circulating miRNAs may serve as heterotypic signaling 
molecules for intercellular communication by functioning 
in recipient cells [17]. 
Breast cancer is the most common non-
dermatological cancer in women. Although the 5-year 
survival has reached around 98% in localized breast 
cancer [18], metastatic breast cancer, which occurs in 
20%–30% of breast cancer patients, remains incurable 
partly due to the lack of a reliable biomarker for early 
diagnosis before metastasis occurs [19]. miRNAs regulate 
breast cancer initiation and progression functioning as 
either tumor suppressors or oncogenes [6, 20]. Altered 
expression of miRNAs or mutation of miRNA genes 
have been described in human breast cancer. As early as 
in 2005, Lorio et al identified 29 miRNAs with aberrant 
expression in human breast cancer by analysis on 76 breast 
tumor samples and 14 human breast cell lines [21]. Zhang 
and his colleagues analyzed 283 human miRNA genes in 
55 human breast primary tumors and 18 human breast 
cancer cell lines, demonstrating a high frequency (~72.8%) 
of gene copy number abnormality in miRNA-containing 
regions in human breast cancer [22]. A growing body of 
evidence implicates miRNAs in regulating breast cancer 
metastasis as well as epithelial to mesenchymal transition 
(EMT). 
Although the function of circulating miRNAs in 
breast cancer is not well understood, emerging evidence 
suggests circulating miRNA may be important in 
diagnosis and prognosis of breast cancer. Circulating 
miRNA in blood of breast cancer patients demonstrate 
increased levels of miR-195 and let-7a compared to 
control subjects [23]. A recent report proposed miR-181 
a-5p as a diagnostic breast cancer biomarker because 
of a significant reduction of circulating miR-181a-5p 
level in breast cancer patients’ serum [24]. However, the 
circulating miRNAs in metastatic breast cancer remains 
to be determined. 
Currently methods for circulating miRNA analysis 
are mainly based on RNA purification and small RNA 
enrichment. It is unavoidable to have part of the circulating 
miRNAs lost due to the incomplete denaturation of protein 
and/or incomplete precipitation of RNA, which may lead 
to failure to detect low abundance miRNAs. Yoon et al 
reported an assay to detect mRNA and miRNA directly 
from cell lysates (cell to Ct) without RNA isolation 
[25]. Sota et al reported a direct serum assay for miRNA 
analysis in cancer patient [26]. Both reports lacked 
evaluation of the specificity, accuracy and efficiency 
of the direct approach, which limits the reliability and 
applicability. In the present study we optimized a simple, 
effective and time-saving method to directly measure the 
plasma miRNA without RNA purification. The method is 
based on a complete denaturation of miRNA-containing 
microvesicles and/or exosomes, miRNA release from 
those complexes, followed by miRNA-specific reverse 
transcription and quantitative real-time PCR amplification 
(QRT-PCR). RNA isolation and purification is not required 
in this assay. It greatly shortens the time and decreases the 
cost for the circulating miRNAs measurement compared 
to the traditional RNA-based assays. More importantly, 
the direct quantification method showed more efficiency 
for measuring circulating miRNAs compared to the RNA-
based approaches. By applying the direct quantification 
method, we validated changes in circulating miR-106a 
levels in metastatic breast cancer, and proved evidence 
for the potential as a biomarker specifically for metastatic 
human breast cancer. 
RESULTS
Direct quantification of circulating miRNAs 
from plasma without RNA purification
In order to determine how circulating miRNAs can 
be released efficiently from microvesicles and exosomes 
in blood and whether the released miRNAs can be directly 
amplified for quantitative analysis, different methods for 
denaturing protein, including chemical detergents and 
heating treatment, were compared.  As shown in Figure 1A, 
aliquots of 5 µl plasma were treated by M1 (75°C for 5 min 
alone), M2 (treated with same volume of denaturing buffer 
containing Tween20, Tris and EDTA) or M3 (denaturing 
buffer reaction followed by heat treatment), respectively. 
The released circulating miRNAs were immediately 
reverse-transcribed to cDNA without further RNA 
purification. Using the cDNA as template, two of the most 
abundant small RNAs in plasma, 5s rRNA and miR-16, 
were amplified by QRT-PCR reaction (Figure 1B and 1C). 
For both 5s rRNA (Figure 1B) and miR-16 (Figure 1C), 
M3 showed the highest efficiency for gene amplification, 
M1 showed less efficiency (M1 vs M3, ∆Ct ~1 cycle) 
while M2 showed the lowest efficiency (M2 vs M3, 
∆Ct ~10 cycles). The results demonstrated the feasibility 
of circulating miRNAs direct amplification using plasma 
without RNA purification, and indicated that approach 
M3 has the highest efficiency to release miRNAs from 
protein complexes for further analysis. SDS, which is used 
the most frequently for protein denaturation, was tested 
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to release circulating miRNAs from protein complexes, 
followed by a miRNA direct quantification analysis. As 
shown in Supplementary Figure S1, none of the three 
tested small RNAs were amplified after SDS treatment, 
indicating the existence of SDS in the reaction system may 
have severe inhibition to miRNA amplification.
The accuracy of the plasma-based direct 
quantification of circulating miRNAs
In order to evaluate the accuracy of the plasma-
based method for circulating miRNA analysis, different 
volumes of plasma (1 µl, 4 µl, and 8 µl) from the same 
donor were treated in parallel using method M3, followed 
by reverse transcription and QRT-PCR amplification of 
miR-16 (Figure 2A–2C). 1 µl, 4 µl, and 8 µl of the plasma 
yielded Ct values around 31.8, 29.6 and 28.5 cycles, 
respectively (Figure 2A and 2B). The Log2 ∆Ct had a 
perfect correlation with the plasma volume (Figure 2C) 
indicating the miRNA quantification result reflects the real 
abundance of miR-16 in the reaction system. 
In addition, direct quantification of circulating 
miRNAs was performed in multiple plasma samples with 
different dilutions of cDNA to validate the accuracy of the 
method.  Three plasma samples from randomly selected 
three donors were tested for miR-16. cDNAs from 
plasma specimens S1, S2 and S3 were diluted by 1:10 
and 1:100, respectively (Figure 2D). Circulating miR-16 
was analyzed in all diluted cDNAs. The results showed 
~3.3 ∆Ct between 1:10 and 1:100 diluted cDNAs in all 
the three tested samples (Figure 2D and 2E), representing 
the average fold change 10.27 ± 0.61 of the miR-16 
abundance in 1:10 compared with 1:100 diluted cDNAs 
(Figure 2F). In addition to miR-16, miR-92a and let-7b 
Figure 1: Direct quantification of circulating miRNAs using plasma. (A) Schematic representation of the three methods 
(M1, M2 and M3) directly analyzing circulating miRNAs from plasma. (B) QRT-PCR analysis of small RNA 5s rRNA from aliquots of 
same plasma sample using methods M1, M2 and M3, respectively. (C) QRT-PCR analysis of miR-16 from aliquots of same plasma sample 
using methods M1, M2 and M3, respectively.
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were also measured in S1 cDNA diluted by 1:10 and 
1:100. Similar to miR-16, both miR-92a (Supplementary 
Figure S2) and let-7b (Supplementary Figure S3) showed 
∆Ct around 3.3–3.5 cycles which is consistent with the 
10-fold difference in cDNA concentration. 
The specificity of the plasma-based direct 
quantification of circulating miRNAs
In order to determine the specificity of the direct 
quantification method for circulating miRNA analysis, an 
exogenous small RNA named unisp6 was added into either 
purified RNA or the original plasma for further analysis. 
Firstly it was tested in the RNA sample to ensure the 
exogenous RNA is able to be amplified well. 2 µl of unisp6 
(1 µl equals to 108 copies) was added to a RNA sample 
followed by a miRNA reverse transcription reaction. 
The cDNA was diluted with 1:10 and 1:100 followed by 
a PCR amplification. Accordingly, the results showed 
Ct values 20.8 ± 0.14 and 24.4 ± 0.15 corresponding to 
the two diluted cDNAs (Figure 3A), while the control 
RNA (without adding unisp6) only had a background 
signal. Data analysis indicated the fold change of unisp6 
abundance is consistent with the cDNA concentration 
(Figure 3B). Similarly, 2 µl of unisp6 was added directly 
to a plasma sample for a small RNA quantitative analysis 
using the method M3. Unisp6 was undetectable in control 
sample, while it had Ct values of 26.44 ± 0.12 and 
29.83 ± 0.14 in 1:10 and 1:100 diluted cDNAs, 
respectively (Figure 3C). The ~ 10-fold change of unisp6 
abundance is consistent with the cDNA concentration 
(Figure 3D).
In addition, different amount of unisp6 (0, 1, and 
4 µl) were added into aliquots of plasma samples, followed 
by protein denaturation, reverse transcription and PCR 
amplification. As expected, unisp6 was undetectable in 
Figure 2: High accuracy of the plasma-based direct quantification of circulating miRNAs. (A) Quantitative analysis of 
miR-16 from 1, 4 and 8 µl of plasma sample using methods M3. (B) Ct values in A analysis. (C) The miR-16 abundance showed a linear 
positive correlation with the plasma volume with R2 = 0.999. (D) Quantitative analysis of miR-16 from three different plasma samples 
(S1, S2 and S3) with 1:10 and 1:100 cDNA dilutions. (E) Actual Ct values and fold changes of miR-16 abundance in the three samples at 
cDNA dilution 1:10 vs 1:100. (F) miR-16 abundance showed 10.27 times more in 1:10 than 1:100 diluted cDNAs, which is consistent with 
cDNA concentration.
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the reaction with 0 µl unisp6. The expression levels of 
unisp6 correlated with the amount of unisp6 added into the 
plasma (Figure 3E). As a form of control, the abundance 
of two endogenous small RNAs, miR-16 and 5s rRNA, 
did not show change between these samples (Figure 3F 
and 3G). Another set of experiments with 0, 2 and 4 µl of 
unisp6 added into a plasma sample further confirmed the 
specificity and accuracy of this direct quantitative method 
for circulating miRNA analysis (Supplementary Figure S4, 
S5 and S6).
The results also reflected the sensitivity of the method. 
As indicated in Supplementary Figure S5, 2 µl of unisp6, 
which equals 2 × 108 copies, gave a Ct value about 28 cycles 
for unisp6 amplification. Since Ct values of over 35 cycles 
are considered as undetectable level, a minimum of ~106 
copies of unisp6 in plasma will be having a maximum Ct of 
35 cycles by calculation. As such, 106 copies of miRNA can 
be considered as sensitivity limit for the method. In order to 
confirm this sensitivity limit, additional experiments were 
performed by adding 0 µl, 0.25 µl, 1.0 µl of exogenous 
unisp6 into same volume of plasma, followed by a direct 
quantification of unnisp6 and 5s rRNA. As shown in 
Supplementary Figure S7, Ct values of 30 cycles and 
28 cycles corresponded to 0.25 µl and 1.0 µl of unisp6, 
respectively. It is consistent with other data demonstrating 
the sensitivity limit of 106 copies of miRNAs.
The efficiency of the plasma-based direct 
quantification of circulating miRNAs
In order to determine the efficiency of the plasma-
based method for measuring circulating miRNAs, 
selected plasma samples were either treated with 
Trizol to isolate RNA or treated following the M3 
Figure 3: High specificity of the plasma-based direct quantification of circulating miRNAs. (A) QRT-PCR analysis of an 
exogenous small RNA unisp6 which was added into purified RNA with 1:10 and 1:100 dilutions to cDNA. (B) Quantitative analysis of 
unisp6 abundance in A. (C) QRT-PCR analysis of exogenous small RNA unisp6 which was added into plasma with 1:10 and 1:100 dilutions 
to cDNA. (D) Quantitative analysis of unisp6 abundance in C. (E) Quantitative analysis of exogenous small RNA unisp6 which was added 
into plasma with volume 0, 1 and 4 µl. (F) Quantitative analysis of miR-16 in all cDNAs of E. (G) Quantitative analysis of 5s rRNA in all 
cDNAs of E.
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protocol to release miRNA from protein complexes. 
The RNA-based and plasma-based methods were 
compared for circulating miRNA analysis in three 
randomly selected plasma samples as shown in 
Figure 4A–4D. For each sample, identical amounts of 
cDNA either derived from purified RNA or derived 
directly from plasma were used to measure let-7b and 
miR-92a, two circulating miRNAs related to cancer. In both 
sample S2 and S3, the plasma-based direct quantification 
method showed smaller Ct values, ~0.7–1.1 cycles of 
∆Ct compared to the RNA-based method (Figure 4C 
and 4D). It is indicative of a higher efficiency of the 
plasma-based direct quantification method for circulating 
miRNA analysis. 
In addition, the expression of circulating let-7b and 
miR-92a was analyzed in two randomly selected plasma 
samples (S4 and S5) and compared using either the RNA-
based method or the plasma-based direct quantification 
method (Figure 4E and 4F). Both methods indicated 
higher levels of let-7b and miR-92a in S4 than that in S5 
(Figure 4G). Furthermore, for both let-7b and miR-92a, 
∆∆Ct value between the two methods showed a linear 
correlation with R2 equals 1.0 (Figure 4H and 4I), 
demonstrating the high accuracy of the plasma-based 
direct quantification of circulating miRNA. 
The stability of circulating miRNAs and the 
reproducibility of the plasma-based direct quantification 
method were also tested using plasma samples stored 
at a −80°C stored at day 1 and day 5 to measure the 
abundance of miR-16 (Supplementary Figure S8) and 
let-7b (Supplementary Figure S9). The Ct value showed 
strong stability for both miRNA at day 1 and day 
5, indicating the stability of circulating miRNAs and 
the reproducibility of the direct quantitation method for 
miRNA analysis.
Identification of circulating miRNAs as novel 
biomarkers for detecting metastatic breast 
cancer
Emerging evidence has demonstrated the potential 
of circulating miRNAs as biomarkers for early detection of 
cancer. We applied the plasma-based direct quantification 
method combined with the RNA-based method to validate 
a circulating miRNA signature in metastatic breast cancer. 
Total RNA was isolated from six plasma specimens 
of breast cancer patients including three lymph node 
positive (LN+) and three lymph node negative (LN−). 
Comparison was made with four normal control samples 
from age-matched healthy females. QRT-PCR based 
miRNA detection panels, which contain 365 cancer related 
miRNAs, were interrogated to detect the circulating 
miRNA profile in the six cancer specimens and the four 
normal controls. The results found three significantly 
upregulated circulating miRNAs (miR-20b, miR-106a 
and miR-16) and four downregulated circulating miRNAs 
(miR-671, miR-151-3p, miR-433 and miR-409-3p) in 
breast cancer (Figure 5A). In order to further validate the 
results, the plasma-based direct quantification method 
was applied to measure the abundance of these miRNAs 
in an additional three LN+, three LN− and three normal 
control plasma samples. The upregulation of miR-106a 
was confirmed in plasma samples from metastatic breast 
cancer patients (Figure 5B), which is consistent with the 
circulating miRNA screening results (Figure 5A). Notably, 
upregulation trend of circulating miR-20b (Supplementary 
Figure S10) and downregulation trend of circulating 
miR-671 were observed in the metastatic breast cancer 
patients. Circulating miR-409-3p showed downregulation 
trend in both LN+ and LN− breast cancer patients 
(Supplementary Figure S11). However p value did not 
show significance change due to the small number of 
samples. Still these results provided a subset of candidate 
circulating miRNAs as potential biomarkers for metastatic 
breast cancer.
In order to further confirm the upregulation of 
circulating miR-106a in metastatic breast cancer patients, 
additional plasma samples from 10 metastatic breast 
cancer patients and 10 control females were collected to 
test and compare the levels of circulating miR-106a. As 
shown in Supplementary Figure S12, the upregulation of 
circulating miR-106a in metastatic breast cancer patients 
was confirmed. Although the upregulation of circulating 
miR-20b and downregulation of Circulating miR-671 
showed the trend in the metastatic breast cancer, it still 
needs further validation by analysis on an enlarged set of 
samples.
DISCUSSION
Although nucleic acids was first demonstrated 
in human blood in 1948 [27], the source, structure and 
function of the nucleic acids and their relationship to 
human diseases was not exploited until early this century 
[28, 29]. The nucleic acids in plasma and serum include 
DNA, mRNA, miRNA and lncRNA. The nucleic acids 
may be released from blood cells, necrosed cell and 
tissues, apoptotic cells, exosomes and DNA/RNA-
lipoprotein complexes [30]. Changes in the levels of 
circulating nucleic acids have been associated with 
pathological conditions including cancer progression. 
Circulating nucleic acids have been demonstrated to have 
potential roles in personalized disease diagnosis, prognosis 
and monitoring of therapeutic efficacy. In addition, nucleic 
acids in blood may also enter cells and exhibit a biological 
activity in the recipient cells [17].
Most of the circulating nucleic acids are protected 
from ribonuclease degradation by association with 
proteins, lipids or lipoprotein complexes, such as 
microvesicles and/or exosomes. Microvesicles, also named 
microparticles, are derived from plasma membranes with 
size ranging from 100 nm to 1000 nm. Exosomes are cell-
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Figure 4: High efficiency of the plasma-based direct quantification of circulating miRNAs. (A) Details of the procedure 
for the RNA-based and plasma-based miRNA analysis for comparison of the two methods. (B–D) Comparison of the RNA-based and 
plasma-based analysis for circulating let-7b and miR-92a in three independent samples S1 (B), S2 (C) and S3 (D). E-F: Comparison of the 
RNA-based and plasma-based analysis for the different expression of let-7b (E) and miR-92a (F) in plasma samples S4 and S5. 
(G) ∆∆Ct value of let-7b and miR-92abetween samples S4 and S5. H-I: The linear correlation with R2 equals 1.0 between the RNA-based and 
plasma-based methods for the different expression analysis of let-7b (H) and miR-92a (I) in samples S4 and S5.
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derived circulating vesicles carrying cell-secreted nucleic 
acids and proteins. Exosomes have a smaller diameter 
of between 30 and 100 nm. Circulating miRNAs are 
protected by protein complexes in forms of microvesicles 
or exosomes. Releasing miRNAs from these particles 
with high efficiency is essential to quantify circulating 
miRNAs. Several methods have been successfully applied 
to quantify circulating miRNAs including miRNA array, 
miRNA real-time PCR, and high-throughput small RNA-
SEQ. These methods are based on RNA isolation or 
small RNA enrichment from serum or plasma.  Isolation 
of small miRNA molecules is inefficient when using the 
regular RNA isolation methods such as RNA purification 
columns. Although Trizol reagent is formulated for 
mRNA isolation, it is applicable for miRNA extraction. 
However, it is unavoidable to have some of the circulating 
miRNAs lost due to incomplete protein denaturation and/
or incomplete RNA precipitation because of the high 
concentration of proteins serum and plasma. Therefore, 
a quantitative analysis of circulating miRNAs with low 
abundances becomes inefficient. 
The feasibility of quantifying the gene expression 
level directly from cell lysates (cell-to-Ct) was primarily 
tested and reported in 2013 [25], where multiple reagents 
were tested and compared for quantification analysis of 
both mRNA and miRNA. Asaga and Hoon reported a 
protocol for direct quantifying circulating miRNA from 
serum [26] but lacking the accuracy and specificity 
examination. Herein we applied a direct quantification 
method combining chemical denaturation and heat 
denaturation to release circulating miRNAs from both 
microvesicles and exosomes followed by a direct 
quantitative PCR amplification. We show this method is 
more efficient with higher accuracy and specificity for 
circulating miRNA analysis, compared with the traditional 
purified RNA-based RT-PCR method.
Circulating miRNAs have potential as biomarkers for 
cancer diagnosis and prognosis. Developing a convenient 
and reliable method with high accuracy and specificity 
to measure circulating miRNAs will be of great benefit 
to both laboratory screening and clinical applications. 
The plasma-based method was successfully applied 
herein to breast cancer clinical samples for screening 
and validating of circulating miRNAs as biomarkers 
for metastatic breast cancer. Changes of miR-106a 
levels in breast cancer patients’ blood were correlated with 
metastatic status. Although miRNAs in blood as potential 
biomarkers for breast cancer has been frequently reported 
[23, 24], it is rare for validation of circulating miRNA as a 
biomarker for metastatic cancer. In addition to miR-106a, 
Figure 5: Identification of circulating miRNAs as novel biomarkers for detecting metastatic breast cancer. (A) Heatmap 
of the circulating miRNA profiling analysis using purified RNAs from three lymph node positive (LN+) and three lymph node negative 
(LN−), as well as four normal control from age-matched healthy females. Three significantly upregulated circulating miRNAs (miR-20b, 
miR-106aand miR-16) and four downregulated circulating miRNAs (miR-671, miR-151-3p, miR-433 and miR-409-3p) in breast cancer 
were identified. (B) The method of plasma-based direct quantification of circulating miRNAs was applied to validate the miRNA signature 
in A, demonstrating significant upregulation of miR-106a in lymph node positive breast cancer patients compared with normal control.
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a subset of circulating miRNAs including miR-20b and 
miR-671, were screened and primarily tested as biomarker 
candidates for metastatic breast cancer. More clinical 
samples are required to further validate the predictive 
value of these candidates for metastatic breast cancer 
before clinical application.
MATERIALS AND METHODS
Plasma collection
Blood samples were collected from breast cancer 
patients and age-matched healthy females at the Shanghai 
East hospital, Department of Surgery. 5 ml of blood were 
collected in EDTA-treated blood-collecting tubes followed 
by a centrifugation at speed of 2,000 rpm for 5 min at 4°C. 
The supernatant was aliquoted and stored at −80°C. All 
the procedures were approved by the Institutional Review 
Board (IRB) of Shanghai East Hospital, Tongji University 
School of Medicine.
Plasma preparation for miRNA measurement 
For circulating miRNA analysis, 5 µl of plasma was 
mixed with 5 µl of denaturing buffer composed of 2.5% 
tween-20, 50 mM Tris and 1 mM EDTA, followed by 
heating in a  water bath at 75°C for 5 min, then cooling on 
ice, and centrifuging at a speed of 12,000 rpm for 10 min 
at 4°C. The supernatant was used for miRNA reverse 
transcription and real-time PCR. 
miRNA QRT-PCR analysis
A M & G miRNA Reverse Transcription kit 
(miRGenes, Shanghai, China) was used to prepare the 
first strand cDNA of plasma miRNAs following the 
manufacturer’s instruction. 5 µl of prepared plasma 
solution or 100 ng of purified total RNA from each 
plasma specimen was used for miRNA measurement. 
After reverse transcription, the cDNA was diluted 1:10-
100 (for plasma method) or 1:200-1000 (for purified RNA 
method) for real-time PCR. The sequences of forward 
primers for miR-92a, miR-16, miR-106a, miR-671, let-7b 
and 5s rRNA are: miR-92a: attgcacttgtcccggcctg; miR-16: 
agcagcacgtaaatattggc; miR-106a: agtgcttacagtgcaggtag; 
miR-671: aggaagcccuggagg; let-7b: tgaggtagtaggttgtgtg; 
5s rRNA: agtacttggatgggagaccg. The DNA oligoes were 
synthesized and purified by GenScript (Nanjing, China). A 
universal reverse primer was provided by miRGenes. The 
spike-in RNA unisp6 and PCR primers for amplify unisp6 
were purchased from Exiqon. 1 µl of unisp6 equals 108 
copies. The SYBR Green Master Mix was ABI product 
(Applied Biosystem, Life Technologies). The ABI 7900 
HT and ABI 7500 Sequence Detection System (Applied 
Biosystem, Life Technologies) were used for quantitative 
real time PCR assay. 5s rRNA was used for normalization 
when necessary.
miRNA profiling analysis in plasma of breast 
cancer patients and normal control
We customized a human cancer-related miRNA 
panel which contains 365 human cancer-related miRNAs 
and 5 reference small RNAs, which was prepared by 
miRGenes (Shanghai, China). Total RNA was isolated 
using Trizol reagent (Life Technologies) from plasma 
specimens. The cDNA was prepared as described above. 
The miRNA expression profiles in plasma specimens 
were performed using the human cancer-related miRNA 
panel, based on the quantitative real-time PCR methods. 
The result was analyzed by Mev (version 4.9) software. 
p < 0.10 was considered significant.
Statistical analysis
Data are presented as mean ± SEM. The standard 
two-tailed Student’s t-test was used for statistical analysis, 
in which P < 0.05 was considered significant.
ACKNOWLEDGMENTS AND FUNDING
This work was supported by Natural Science 
Foundation of China (Grants 81172515 and 81572593), 
Major Program of Development Fund for Shanghai 
Zhangjiang National Innovtaion Demonstration Zone 
ZJ2014-ZD-002. National Basic Research Program of 
China (2012CB966800); partly by grants 13JC1401702 and 
124119a7100 from Science and Technology Commission 
of Shanghai Municipality; partly by the Foundation for 
Innovative Research Groups of the NSFC (81221001); partly 
by grants R01CA070896, R01CA075503, R01CA132115, 
R01CA107382, R01CA086072 (R.G.P.), the Sidney Kimmel 
Cancer Center NIH Cancer Center Core grant P30CA056036 
(R.G.P.). There are no conflicts of interest associated with 
this manuscript.
CONFLICTS OF INTEREST
None.
REFERENCES
 1. International Human Genome Sequencing Consortium. 
Finishing the euchromatic sequence of the human genome. 
Nature. 2004; 431:931–945.
 2. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA 
regulation of a human cellular signaling network. Mol Syst 
Biol. 2006; 2:46.
 3. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, 
Calin GA. miRNAs and their potential for use against 
cancer and other diseases. Future Oncol. 2007; 3:521–537.
 4. Calin GA, Croce CM. MicroRNA signatures in human 
cancers. Nat Rev Cancer. 2006; 6:857–866.
 5. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, 
Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, 
Oncotarget21874www.impactjournals.com/oncotarget
Croce CM. Human microRNA genes are frequently located 
at fragile sites and genomic regions involved in cancers. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2004; 101:2999–3004.
 6. Zhang B, Pan X, Cobb G.P, Anderson TA. microRNAs 
as oncogenes and tumor suppressors. Dev Biol. 2007; 
302:1–12.
 7. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with 
a role in cancer. Nat Rev Cancer. 2006; 6:259–269.
 8. Cummins JM, Velculescu VE. Implications of micro-RNA 
profiling for cancer diagnosis. Oncogene. 2006; 
25:6220–6227.
 9. Kosaka N, Izumi H, Sekine K, Ochiya T. microRNA as a 
new immune-regulatory agent in breast milk. Silence. 2010; 
1:7.
10. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, 
Pulford K, Banham AH, Pezzella F, Boultwood J, 
Wainscoat JS, Hatton CS, Harris AL. Detection of elevated 
levels of tumour-associated microRNAs in serum of 
patients with diffuse large B-cell lymphoma. Br J Haematol. 
2008; 141:672–675.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, 
Pogosova-Agadjanyan EL, Peterson A, Noteboom J, 
O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, 
et al. Circulating microRNAs as stable blood-based markers 
for cancer detection. Proceedings of the National Academy 
of Sciences of the United States of America. 2008; 
105;10513–10518.
12. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, 
Chen J, Guo X, Li Q, Li X, Wang W, et al. Characterization 
of microRNAs in serum: a novel class of biomarkers for 
diagnosis of cancer and other diseases. Cell Res. 2008; 
18;997–1006.
13. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, 
Gibson DF, Mitchell PS, Bennett CF, Pogosova- 
Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. 
Argonaute2 complexes carry a population of circulating 
microRNAs independent of vesicles in human plasma. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2011; 108:5003–5008.
14. Katsuda T, Kosaka N, Ochiya T. The roles of extracellular 
vesicles in cancer biology: toward the development of novel 
cancer biomarkers. Proteomics. 2014; 14:412–425.
15. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in 
body fluid: a new potential biomarker for cancer diagnosis 
and prognosis. Cancer Sci. 2010; 101;2087–2092.
16. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, 
McCue PA, Quong AA, Lisanti MP, Pestell RG. microRNA 
17/20 inhibits cellular invasion and tumor metastasis in 
breast cancer by heterotypic signaling. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2010; 107;8231–8236.
17. Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. 
Circulating miRNAs: cell-cell communication function? 
Front Genet. 2013; 4:119.
18. Chang EL, Lo S. Diagnosis and management of central 
nervous system metastases from breast cancer. The 
oncologist. 2003; 8:398–410.
19. Sanchez-Munoz A, Perez-Ruiz E, Ribelles N, Marquez A, 
Alba E. Maintenance treatment in metastatic breast cancer. 
Expert review of anticancer therapy. 2008; 8:1907–1912.
20. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, 
Whittle J, Ju X, Hyslop T, McCue P, Pestell RG. A cyclin 
D1/microRNA 17/20 regulatory feedback loop in control of 
breast cancer cell proliferation. The Journal of cell biology. 
2008; 182:509–517.
21. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, 
Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, 
Ménard S, Palazzo JP, Rosenberg A, et al. MicroRNA gene 
expression deregulation in human breast cancer. Cancer 
research. 2005; 65:7065–7070.
22. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, 
Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, 
Yao G, Medina A, Oʼbrien-Jenkins A, et al. microRNAs 
exhibit high frequency genomic alterations in human 
cancer. Proceedings of the National Academy of Sciences 
of the United States of America. 2006; 103:9136–9141.
23. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, 
Kerin MJ. Circulating microRNAs as novel minimally 
invasive biomarkers for breast cancer. Ann Surg. 2010; 
251:499–505.
24. Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi 
MV, Rocchi A, Da Ros L, Zagatti B, Musa G, Bassi C, 
Mangolini A, Cavallesco G, Frassoldati A, et al. Absolute 
quantification of cell-free microRNAs in cancer patients. 
Oncotarget. 2015; 6:14545–14555. doi: 10.18632/
oncotarget.3859.
25. Ho Y.K, Xu WT, Too HP. Direct quantification of mRNA 
and miRNA from cell lysates using reverse transcription real 
time PCR: a multidimensional analysis of the performance 
of reagents and workflows. PloS one. 2013; 8:e72463.
26. Asaga S, Hoon DS. Direct serum assay for microRNA in 
cancer patients. Methods Mol Biol. 2013; 1024:147–155.
27. Mandel P, Metais P. Les acids nucleiques du plasma 
sanguine chez l’homme. C R Seances Soc Biol Fil. 1948; 
142:241–243.
28. Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, 
Lo YM. Prognostic use of circulating plasma nucleic acid 
concentrations in patients with acute stroke. Clin Chem. 
2003; 49:562–569.
29. Lam NY, Rainer TH, Chan LY, Joynt G.M, Lo YM. Time 
course of early and late changes in plasma DNA in trauma 
patients. Clin Chem. 2003; 49:1286–1291.
30. Gahan PB, Stroun M. The biology of circulating nucleic 
acids in plasma and serum. In: Rykova EY, Kikuchi Y, 
editors. Extracellular nucleic acids. In Series “Nucleic 
Acids and Molecular Biology” Springer Berlin. 2010.
